The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...
Semglee™ (insulin glargine injection; Mylan and Biocon Biologics) is now available to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes.
(RTTNews) - Mylan Pharmaceuticals Inc., affiliated to healthcare company Viatris Inc., is recalling certain Insulin Glargine (Insulin glargine-yfgn) Injection prefilled pens due to the potential for ...
Mylan Pharmaceuticals recalled one batch of Insulin Glargine Injection, 100 units/mL (U-100), 3 mL prefilled pens, which are sold in cartons of five. Some pens might be missing their labels. In ...
Mylan and Biocon’s NDA for Semglee (insulin glargine injection), was approved last week by the FDA, making it the third product approved by the FDA through the Mylan-Biocon Biologics collaboration.
After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.
Semglee available in vial and pen presentations at a 65% discounted list price, the lowest available for a long-acting insulin glargine on the market HERTFORDSHIRE, England and PITTSBURGH and ...
Sanofi cuts U.S. list price of Lantus ®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance Paris, March 16, 2023. Sanofi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results